With 1,952 Cell & Gene Therapy related patents published between 2002 and 2022, Johnson & Johnson holds the most number of Cell & Gene Therapy patents in the global Healthcare sector, of which 15.2% was contributed by its subsidiary Johnson & Johnson Surgical Vision Inc.
The second largest number of Cell & Gene Therapy related patents were published by Alcon Inc with 1,345 patents. The third largest number of Cell & Gene Therapy related patents were published by Stryker Corp with 1,186 patents. The fourth largest number of Cell & Gene Therapy related patents were published by Medtronic Plc with 973 patents, of which 43.9% was contributed by its subsidiary Warsaw Orthopedic, Inc.. The fifth largest number of Cell & Gene Therapy related patents were published by University of California with 921 patents, of which 70.8% was contributed by its subsidiary Regents of the University of California.
The top five patent holders, i.e., Johnson & Johnson, Alcon Inc, Stryker Corp, Medtronic Plc, and University of California, together held 6,377 Cell & Gene Therapy patents during the period.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
United States of America
United States of America
Japan
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer